Provided by Tiger Trade Technology Pte. Ltd.

Oculis

10.14
+0.16001.60%
Post-market: 10.00-0.1400-1.38%19:52 EDT
Volume:411.95K
Turnover:4.12M
Market Cap:625.96M
PE:-5.91
High:10.43
Open:10.17
Low:9.67
Close:9.98
52wk High:34.48
52wk Low:9.65
Shares:61.73M
Float Shares:53.44M
Volume Ratio:1.87
T/O Rate:0.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7151
EPS(LYR):-2.3888
ROE:-43.70%
ROA:-24.95%
PB:2.35
PE(LYR):-4.24

Loading ...

Oculis Holding Price Target Raised to $39.00/Share from $26.00 by HC Wainwright & Co.

Dow Jones
·
Yesterday

Oculis price target raised to $39 from $26 at H.C. Wainwright

TIPRANKS
·
Yesterday

Oculis Holding Ag : H.c. Wainwright Raises Target Price to $39 from $26

THOMSON REUTERS
·
Yesterday

Mitie Shareholders Back OCS Cash Takeover, Deal Set for 2027 Completion

TIPRANKS
·
Sep 16

Mitie Directors Strengthen Support for OCS Cash Takeover

TIPRANKS
·
Aug 25

Oculis: Advancing Privosegtor in Optic Neuritis and MS Relapses Supports Buy Rating and Unchanged $26 Price Target

TIPRANKS
·
Aug 24

Oculis Treats First Patient in Optic Neuritis Trial; Shares Up Pre-Bell

MT Newswires Live
·
Aug 24

The Real Market Driver Right Now Might Surprise You

Deep News
·
Aug 20

HUBER+SUHNER boosts orders and bets on OCS and test solutions amid margin pressure

TIPRANKS
·
Aug 18

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
Aug 15

Oculis Holding Price Target Cut to $20.00/Share from $23.00 by JP Morgan

Dow Jones
·
Aug 15

J.P. Morgan Gives a Buy Rating to Oculis Holding (OCS)

TIPRANKS
·
Aug 14

Press Release: UTStarcom Reports Unaudited Financial Results for First Half of 2026

Dow Jones
·
Aug 14

Mitie Corrects Voting Rights Ahead of OCS Takeover as Directors Back Scheme

TIPRANKS
·
Aug 12

Oculis to acquire development, commercial rights to Privosegtor from Accure

TIPRANKS
·
Aug 10

Oculis to Buy Accure's Global Development, Commercial Rights to Privosegtor

MT Newswires Live
·
Aug 10

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

GlobeNewswire
·
Aug 10

Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Xenon (XENE)

TIPRANKS
·
Aug 08

Oculis Holding Q2 EPS $(0.20) Beats $(0.48) Estimate, Sales $392.150K Beat $260.000K Estimate

Benzinga Earnings
·
Aug 07

Oculis Holding AG Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07